CD200-expressing human basal cell carcinoma cells initiate tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 4, 2013, Pages 1434-1439

  Colmont, Chantal S ^a   BenKetah, Antisar ^a   Reed, Simon H ^a   Hawk, Nga V ^b   Telford, William G ^b   Ohyama, Manabu ^c   Udey, Mark C ^b   Yee, Carole L ^b   Vogel, Jonathan C ^b   Patel, Girish K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD45 ANTIGEN; PROTEIN INHIBITOR; SMOOTHENED ANTAGONIST; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INOPERABLE CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; CARCINOMA, BASAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; KERATINS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; RECEPTORS, G-PROTEIN-COUPLED; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

ERINACEIDAE;

EID: 84872873292     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211655110     Document Type: Article

References (48)

1. American Cancer Society (2012) Cancer Facts and Figures 2012. Available at: www. cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts- figures-2012. Accessed March 3, 2012.
2. Johnson RL, et al. (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272(5268):1668-1671.
3. Grachtchouk M, et al. (2000) Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet 24(3):216-217.
4. Hahn H, et al. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85(6):841-851.
5. Oro AE, et al. (1997) Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276(5313):817-821.
6. Xie J, et al. (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90-92.
7. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A (1997) Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 389(6653):876-881.
8. Fan H, Oro AE, Scott MP, Khavari PA (1997) Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 3(7):788-792.
9. Epstein EH (2008) Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer 8(10):743-754.
10. McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1-114.
11. Bhardwaj G, et al. (2001) Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2(2):172-180.
12. Scales SJ, de Sauvage FJ (2009) Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30(6):303-312.
13. Jiang J, Hui CC (2008) Hedgehog signaling in development and cancer. Dev Cell 15(6): 801-812.
14. Tremblay MR, et al. (2009) Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52(14):4400-4418.
15. De Smaele E, Ferretti E, Gulino A (2010) Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 11(6):707-718.
16. Tremblay MR, McGovern K, Read MA, Castro AC (2010) New developments in the discovery of small molecule Hedgehog pathway antagonists. Curr Opin Chem Biol 14 (3):428-435.
17. Von Hoff DD, et al. (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164-1172.
18. Metcalfe C, de Sauvage FJ (2011) Hedgehog fights back: Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 71(15):5057-5061.
19. Skvara H, et al. (2011) Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 131(8):1735-1744.
20. Sekulic A, et al. (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171-2179.
21. Tang JY, et al. (2012) Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366(23):2180-2188.
22. Grachtchouk V, et al. (2003) The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 22(11):2741-2751.
23. Hutchin ME, et al. (2005) Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: Conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19(2):214-223.
24. Yang SH, et al. (2008) Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet 40(9):1130-1135.
25. Grachtchouk M, et al. (2011) Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest 121(5):1768-1781.
26. Wang GY, Wang J, Mancianti ML, Epstein EH, Jr. (2011) Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 19(1):114-124.
27. Youssef KK, et al. (2010) Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 12(3):299-305.
28. Schweizer J, Langbein L, Rogers MA, Winter H (2007) Hair follicle-specific keratins and their diseases. Exp Cell Res 313(10):2010-2020.
29. Bianchi N, Depianto D, McGowan K, Gu C, Coulombe PA (2005) Exploiting the keratin 17 gene promoter to visualize live cells in epithelial appendages of mice. Mol Cell Biol 25(16):7249-7259.
30. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA (2010) Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet 42(10):910-914.
31. Ohyama M, et al. (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 116(1):249-260.
32. Patel GK, et al. (2012) Identification and characterization of tumor-initiating cells in human primary cutaneous squamous cell carcinoma. J Invest Dermatol 132(2):401-409.
33. Regl G, et al. (2002) Human GLI2 and GLI1 are part of a positive feedback mechanism in basal cell carcinoma. Oncogene 21(36):5529-5539.
34. Patel GK, Yee CL, Yuspa SH, Vogel JC (2012) A humanized stromal bed is required for engraftment of isolated human primary squamous cell carcinoma cells in immunocompromised mice. J Invest Dermatol 132(2):284-290.
35. Lyle S, et al. (1998) The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 111(Pt 21):3179-3188.
36. Segre JA, Bauer C, Fuchs E (1999) Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet 22(4):356-360.
37. Gandarillas A, Watt FM (1997) c-Myc promotes differentiation of human epidermal stem cells. Genes Dev 11(21):2869-2882.
38. Fan H, Khavari PA (1999) Sonic hedgehog opposes epithelial cell cycle arrest. J Cell Biol 147(1):71-76.
39. Minas K, Liversidge J (2006) Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol 26(3):213-230.
40. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B (2008) CD200: A putative therapeutic target in cancer. Biochem Biophys Res Commun 366(1):117-122.
41. Wright GJ, et al. (2003) Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171(6):3034-3046.
42. Hoek RM, et al. (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290(5497):1768-1771.
43. Terunuma A, et al. (2008) Behavior of human foreskin keratinocytes expressing a hair follicle stem cell marker CD200. J Invest Dermatol 128(5):1332-1334.
44. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364(4):778-782.
45. Kawasaki BT, Farrar WL (2008) Cancer stem cells, CD200 and immunoevasion. Trends Immunol 29(10):464-468.
46. Moreaux J, et al. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194-4197.
47. Tonks A, et al. (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3):566-568.
48. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988.